1
|
Huang YY, Chang LT, Shen HY, Chen YH, Tzen KY, Shiue CY, Hsin LW. Synthesis and evaluation of 2-(2'-((dimethylamino)methyl)-4'-(2-fluoroethoxy-substituted)phenylthio)benzenamine derivatives as potential positron emission tomography imaging agents for serotonin transporters. Bioorg Chem 2020; 97:103654. [PMID: 32088418 DOI: 10.1016/j.bioorg.2020.103654] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/30/2020] [Accepted: 02/05/2020] [Indexed: 10/25/2022]
Abstract
A series of diphenylsulfide derivatives with various substitutions at the 4-position on phenyl ring A and different lengths of the 2-fluoroethoxy-substituted side-chain at the 4'-position on ring B were synthesized and evaluated as potential positron emission tomography (PET) imaging agents for serotonin transporters (SERT). These ligands exhibited high SERT binding affinities (Ki = 0.11-1.3 nM) and the 4-methyl-substituted (4-Me) compounds 7a and 8a displayed excellent selectivity for SERT versus norepinephrine transporters (NET) (392- and 700-fold, respectively). In the parallel artificial membrane permeability assay (PAMPA), these ligands demonstrated moderate to high brain penetration, and the 4-Me analogs showed higher BBB permeability than the corresponding 4-F analogs. The 2-fluoroethoxy-substituted ligands showed higher metabolic stability and lower lipophilicity than 4-F-ADAM. [18F]7a-c were readily prepared using an automatic synthesizer and exhibited significant uptake and slow washout in rat brains. At 120 min after iv injection, [18F]7a exhibited the highest uptake in the midbrain, whereas [18F]7b exhibited the highest uptake in the hypothalamus and midbrain. After treatment with citalopram, a SERT-selective ligand, the uptake of [18F]7a in the hypothalamus and striatum was significantly decreased. The potent and highly selective SERT binding and the selective and reversible accumulation in SERT-rich brain regions suggested that [18F]7a is a promising lead for the further development of novel [18F]-labeled PET imaging agents for SERT binding sites in the brain.
Collapse
Affiliation(s)
- Ya-Yao Huang
- PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Road, Taipei, Taiwan
| | - Li-Te Chang
- School of Pharmacy, College of Medicine, National Taiwan University, 17, Xuzhou Road, Room 936, Taipei 10055, Taiwan
| | - Hsin-Yi Shen
- School of Pharmacy, College of Medicine, National Taiwan University, 17, Xuzhou Road, Room 936, Taipei 10055, Taiwan
| | - Ying-Heng Chen
- School of Pharmacy, College of Medicine, National Taiwan University, 17, Xuzhou Road, Room 936, Taipei 10055, Taiwan
| | - Kai-Yuan Tzen
- PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Road, Taipei, Taiwan
| | - Chyng-Yann Shiue
- PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Road, Taipei, Taiwan.
| | - Ling-Wei Hsin
- School of Pharmacy, College of Medicine, National Taiwan University, 17, Xuzhou Road, Room 936, Taipei 10055, Taiwan; Center for Innovative Therapeutics Discovery, National Taiwan University, 17, Xuzhou Road, Room 936, Taipei 10055, Taiwan.
| |
Collapse
|
2
|
Tiwari AD, Zhu J, You J, Eck B, Zhu J, Wang X, Wang X, Wang B, Silver J, Wilson D, Wu C, Wang Y. Novel 18F-Labeled Radioligands for Positron Emission Tomography Imaging of Myelination in the Central Nervous System. J Med Chem 2019; 62:4902-4914. [PMID: 31042384 DOI: 10.1021/acs.jmedchem.8b01354] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Myelin is the protective sheath that surrounds nerves in vertebrates to protect axons, which thereby facilitates impulse conduction. Damage to myelin is associated with many neurodegenerative diseases such as multiple sclerosis and also includes spinal cord injury (SCI). The small size of the spinal cord poses formidable challenges to in vivo monitoring of myelination, which we investigated via conducting a structure-activity relationship study to determine the optimum positron-emitting agent to use for imaging myelin using positron emission tomography (PET). From these studies, [18F]PENDAS was identified as the lead agent to use in conjunction with PET imaging to delineate the integrity of spinal cord myelin. A subsequent in vivo PET imaging study of [18F]PENDAS in rats with SCI showed promising pharmacokinetic results that justify further development of imaging markers for diagnosing myelin-related diseases. Additionally, [18F]PENDAS could be valuable in determining the efficacy of therapies that are currently under development.
Collapse
Affiliation(s)
| | | | | | | | | | - Xu Wang
- Department of Radiology , Binzhou Medical University , Binzhou , Shandong 256603 , China
| | - Xizhen Wang
- Department of Radiology , Weifang Medical University , Weifang , Shandong 261053 , China
| | - Bin Wang
- Department of Radiology , Binzhou Medical University , Binzhou , Shandong 256603 , China
| | | | | | | | - Yanming Wang
- Department of Radiology , Binzhou Medical University , Binzhou , Shandong 256603 , China
| |
Collapse
|
3
|
Liu F, Zhu L, Choi SR, Plössl K, Zha Z, Kung HF. Deuterium-substituted 2-(2′-((dimethylamino)methyl)-4′-[18
F](fluoropropoxy)phenylthio)benzenamine as a serotonin transporter imaging agent. J Labelled Comp Radiopharm 2018; 61:576-585. [DOI: 10.1002/jlcr.3626] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 03/28/2018] [Accepted: 03/29/2018] [Indexed: 01/06/2023]
Affiliation(s)
- Futao Liu
- Key Laboratory of Radiopharmaceuticals, Ministry of Education; Beijing Normal University; Beijing P. R. China
- Department of Radiology; University of Pennsylvania; Philadelphia Pennsylvania USA
| | - Lin Zhu
- Key Laboratory of Radiopharmaceuticals, Ministry of Education; Beijing Normal University; Beijing P. R. China
| | - Seok Rye Choi
- Department of Radiology; University of Pennsylvania; Philadelphia Pennsylvania USA
| | - Karl Plössl
- Department of Radiology; University of Pennsylvania; Philadelphia Pennsylvania USA
| | - Zhihao Zha
- Department of Radiology; University of Pennsylvania; Philadelphia Pennsylvania USA
| | - Hank F. Kung
- Department of Radiology; University of Pennsylvania; Philadelphia Pennsylvania USA
- Five Eleven Pharma Inc; Philadelphia Pennsylvania USA
| |
Collapse
|
4
|
Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening. J Pharm Biomed Anal 2018. [PMID: 29533858 DOI: 10.1016/j.jpba.2018.02.063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Cassette dosing is also known as N-in-One dosing: several compounds are simultaneously administrated to a single animal and then the samples are rapidly detected by LC-MS/MS. This approach is a successful strategy to enhance the efficiency of drug discovery and reduce animal usage. However, no report on the utility of the cassette approach in radiotracer discovery has appeared in the literature. This study designed a cassette microdose with LC-MS/MS method to enhance the throughput for screening radiopharmaceutical biodistribution in the rat brain directly. Three unradiolabeled compounds (FPBM FPBM2 and AV-133) were chosen as model drugs administrated intravenously to the rats as a cassette as opposed to discrete study. The rat brain biodistribution data, target localization, the differential uptake ratio (%ID/g) and the brain tissue-specific binding ratio were obtained by the LC-MS/MS analysis. These data matched very well with the values obtained by the standard radioactivity measurements. Moreover, no significant differences between discrete dosing and cassette dosing were observed. By circumventing the need for radiolabeled molecules, this method may be high-throughput and safe for the research and development of new PET imaging agents. The combination of cassette microdosing and LC-MS/MS would be a medium throughput screening tool at an early stage in the discovery/development process of PET imaging agents.
Collapse
|
5
|
Stehouwer JS, Goodman MM. Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine. PET Clin 2016; 4:101-28. [PMID: 20216936 DOI: 10.1016/j.cpet.2009.05.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
This review focuses on the development of fluorine-18 radiolabeled PET tracers for imaging the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). All successful DAT PET tracers reported to date are members of the 3β-phenyl tropane class and are synthesized from cocaine. Currently available carbon-11 SERT PET tracers come from both the diphenylsulfide and 3β-phenyl nortropane class, but so far only the nortropanes have found success with fluorine-18 derivatives. NET imaging has so far employed carbon-11 and fluorine-18 derivatives of reboxetine but due to defluorination of the fluorine-18 derivatives further research is still necessary.
Collapse
|
6
|
Tiwari AD, Wu C, Zhu J, Zhang S, Zhu J, Wang WR, Zhang J, Tatsuoka C, Matthews PM, Miller RH, Wang Y. Design, Synthesis, and Evaluation of Fluorinated Radioligands for Myelin Imaging. J Med Chem 2016; 59:3705-18. [PMID: 27070324 DOI: 10.1021/acs.jmedchem.5b01858] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Myelination is one of the fundamental processes in vertebrates. A major challenge is to quantitatively image myelin distribution in the central nervous system. For this reason, we designed and synthesized a series of fluorinated radioligands that can be radiolabeled as radiotracers for positron emission tomography (PET) imaging of myelin. These newly developed radioligands readily penetrate the blood-brain barrier and selectively bind to myelin membranes in the white matter region. Structure-activity relationship studies of such ligands suggested that optimal permeability could be achieved with calculated lipophilicty in the range of 3-4. After radiolabeling with fluorine-18, the brain uptake and retention of each radioligand were determined by microPET/CT imaging studies. These pharmacokinetic studies led us to identify a lead compound ([(18)F]FMeDAS, 32) with promising in vivo binding properties, which was subsequently validated by ex vivo autoradiography.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jinming Zhang
- Department of Nuclear Medicine, People's Liberation Army (PLA) General Hospital , Beijing 100853, China
| | | | - Paul M Matthews
- Division of Brain Sciences, Department of Medicine, Imperial College London , London SW12 0NN, United Kingdom
| | - Robert H Miller
- Department of Anatomy and Regenerative Biology, George Washington University , Washington, DC 20037, United States
| | | |
Collapse
|
7
|
Qiao H, Zhang Y, Wu Z, Zhu L, Choi SR, Ploessl K, Kung HF. One-step preparation of [(18)F]FPBM for PET imaging of serotonin transporter (SERT) in the brain. Nucl Med Biol 2016; 43:470-7. [PMID: 27236282 DOI: 10.1016/j.nucmedbio.2016.04.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 03/16/2016] [Accepted: 04/14/2016] [Indexed: 01/27/2023]
Abstract
Serotonin transporters (SERT) in the brain play an important role in normal brain function. Selective serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, escitalopram, etc., specifically target SERT binding in the brain. Development of SERT imaging agents may be useful for studying the function of SERT by in vivo imaging. A one-step preparation of [(18)F]FPBM, 2-(2'-(dimethylamino)methyl)-4'-(3-([(18)F]fluoropropoxy)phenylthio)benzenamine, for positron emission tomography (PET) imaging of SERT binding in the brain was achieved. An active OTs intermediate, 9, was reacted with [(18)F]F(-)/K222 to produce [(18)F]FPBM in one step and in high radiochemical yield. This labeling reaction was evaluated and optimized under different temperatures, bases, solvents, and varying amounts of precursor 9. The radiolabeling reaction led to the desired [(18)F]FPBM in one step and the crude product was purified by HPLC purification to give no-carrier-added [(18)F]FPBM (radiochemical yield, 24-33%, decay corrected; radiochemical purity >99%). PET imaging studies in normal monkeys (n=4) showed fast, pronounced uptakes in the midbrain and thalamus, regions known to be rich in SERT binding sites. A displacement experiment with escitalopram (5mg/kg iv injection at 30min after [(18)F]FPBM injection) showed a rapid and complete reversal of SERT binding, suggesting that binding by [(18)F]FPBM was highly specific and reversible. A one-step radiolabeling method coupled with HPLC purification for preparation of [(18)F]FPBM was developed. Imaging studies suggest that it is feasible to use this method to prepare [(18)F]FPBM for in vivo PET imaging of SERT binding in the brain.
Collapse
Affiliation(s)
- Hongwen Qiao
- Department of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China; Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yan Zhang
- Key Laboratory of Radiopharmaceuticals, Beijing Normal University, Ministry of Education, Beijing, 100875, China
| | - Zehui Wu
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China; Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Lin Zhu
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China; Key Laboratory of Radiopharmaceuticals, Beijing Normal University, Ministry of Education, Beijing, 100875, China; Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
| | - Seok Rye Choi
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Karl Ploessl
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Hank F Kung
- Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China; Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
| |
Collapse
|
8
|
Huang YY, Cheng CY, Huang WS, Ma KH, Tseng TW, Chou TK, Huang Y, Shiue CY. Toxicity and radiation dosimetry studies of the serotonin transporter radioligand [(18) F]AFM in rats and monkeys. EJNMMI Res 2015; 4:71. [PMID: 26116128 PMCID: PMC4452647 DOI: 10.1186/s13550-014-0071-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 11/27/2014] [Indexed: 11/12/2022] Open
Abstract
Background [18 F]AFM is a potent and promising PET imaging agent for the serotonin transporter. We carried out an acute toxicity study in rats and radiation dosimetry in monkeys before the translation of the tracer to humans. Methods Single- and multiple-dose toxicity studies were conducted in Sprague–Dawley rats. Male and female rats were injected intravenously with AFM tartrate as a single dose of 98.7 or 987 μg/kg (592 or 5,920 μg/m2, 100× or 1,000× the proposed human dose of 8 μg, respectively) on day 1 or as five consecutive daily doses of 98.7 μg/kg/day (592 μg /m2/day, 100× human dose, total dose 493.5 μg/kg). PET/CT scans were performed in four Formosan rock monkeys (two males and two females, each monkey scanned twice) using a Siemens BIOGRAPH scanner. After injection of [18 F]AFM (88.5 ± 20.3 MBq), a low-dose CT scan and a series of eight whole-body PET scans in 3-D mode were performed. Time-activity data of source organs were used to calculate the residence times and estimate the absorbed radiation dose using the OLINDA/EXM software. Results In the rats, neither the single dose nor the five daily doses of AFM tartrate produced overt adverse effects clinically. In the monkeys, the radiation doses received by most organs ranged between 8.3 and 39.1 μGy/MBq. The osteogenic cells, red marrow, and lungs received the highest doses of 39.1, 35.4, and 35.1 μGy/MBq, respectively. The effective doses extrapolated to male and female adult humans were 18.0 and 18.3 μSv/MBq, respectively. Conclusions Toxicity studies in Sprague–Dawley rats and radiation dosimetry studies in Formosa rock monkeys suggest that [18 F]AFM is safe for use in human PET imaging studies. Trial registration IACUC-12-200.
Collapse
Affiliation(s)
- Ya-Yao Huang
- PET Center, Department of Nuclear Medicine, Tri-Service General Hospital, 325 Sec. 2, Cheng-Kung Road, Taipei, 114, Taiwan,
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Wu X, Cai H, Ge R, Li L, Jia Z. Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol 2014; 12:551-63. [PMID: 25977680 PMCID: PMC4428027 DOI: 10.2174/1570159x13666141204221238] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 11/22/2014] [Accepted: 12/02/2014] [Indexed: 02/05/2023] Open
Abstract
Parkinson's disease (PD) is a common progressive, neurodegenerative brain disease that is promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements in radionuclide imaging in Parkinson's disease.
Collapse
Affiliation(s)
- Xiaoai Wu
- Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, P.R. China
| | - Huawei Cai
- Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, P.R. China
| | - Ran Ge
- Department of Nuclear Medicine, Fujian Medical University Union Hospital, Fuzhou, P.R. China
| | - Lin Li
- Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, P.R. China
| | - Zhiyun Jia
- Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, P.R. China
| |
Collapse
|
10
|
Zhu L, Li G, Choi SR, Plössl K, Chan P, Qiao H, Zha Z, Kung HF. An improved preparation of [18F]FPBM: A potential serotonin transporter (SERT) imaging agent. Nucl Med Biol 2013; 40:974-9. [DOI: 10.1016/j.nucmedbio.2013.08.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Accepted: 08/04/2013] [Indexed: 10/26/2022]
|
11
|
Jarkas N, Voll RJ, Goodman MM. Synthesis of a phenolic precursor and its efficientO-[18F]fluoroethylation with purified no-carrier-added [18F]2-fluoroethyl brosylate as the labeling agent. J Labelled Comp Radiopharm 2013; 56:539-43. [DOI: 10.1002/jlcr.3046] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 03/07/2013] [Accepted: 03/12/2013] [Indexed: 11/07/2022]
Affiliation(s)
- Nashwa Jarkas
- Department of Radiology and Imaging Sciences; Emory University School of Medicine, Center for Systems Imaging, Wesley Woods Health Center; Atlanta; GA; USA
| | - Ronald J. Voll
- Department of Radiology and Imaging Sciences; Emory University School of Medicine, Center for Systems Imaging, Wesley Woods Health Center; Atlanta; GA; USA
| | - Mark M. Goodman
- Department of Radiology and Imaging Sciences; Emory University School of Medicine, Center for Systems Imaging, Wesley Woods Health Center; Atlanta; GA; USA
| |
Collapse
|
12
|
Stehouwer JS, Goodman MM. 11C and18F PET radioligands for the serotonin transporter (SERT). J Labelled Comp Radiopharm 2013; 56:114-9. [DOI: 10.1002/jlcr.3011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Revised: 10/29/2012] [Accepted: 11/20/2012] [Indexed: 01/03/2023]
Affiliation(s)
- Jeffrey S. Stehouwer
- Center for Systems Imaging, Department of Radiology and Imaging Sciences; Emory University; Atlanta; GA; USA
| | - Mark M. Goodman
- Center for Systems Imaging, Department of Radiology and Imaging Sciences; Emory University; Atlanta; GA; USA
| |
Collapse
|
13
|
Huang WS, Huang SY, Ho PS, Ma KH, Huang YY, Yeh CB, Liu RS, Cheng CY, Shiue CY. PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study. Eur J Nucl Med Mol Imaging 2012; 40:115-24. [PMID: 23053324 DOI: 10.1007/s00259-012-2250-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Accepted: 09/03/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE The aim of this study was to assess the feasibility of using 4-[(18)F]-ADAM as a brain SERT imaging agent in humans. METHODS Enrolled in the study were 19 healthy Taiwanese subjects (11 men, 8 women; age 33 ± 9 years). The PET data were semiquantitatively analyzed and expressed as specific uptake ratios (SUR) and distribution volume ratios (DVR) using the software package PMOD. The SUR and DVR of 4-[(18)F]-ADAM in the raphe nucleus (RN), midbrain (MB), thalamus (TH), striatum (STR) and prefrontal cortex (PFC) were determined using the cerebellum (CB) as the reference region. RESULTS 4-[(18)F]-ADAM bound to known SERT-rich regions in human brain. The order of the regional brain uptake was MB (RN) > TH > STR > PFC > CB. The DVR (n = 4, t* = 60 min) in the RN, TH, STR and PFC were 3.00 ± 0.50, 2.25 ± 0.45, 2.05 ± 0.31 and 1.40 ± 0.13, respectively. The optimal time for imaging brain SERT with 4-[(18)F]-ADAM was 120-140 min after injection. At the optimal imaging time, the SURs (n = 15) in the MB, TH, STR, and PFC were 2.25 ± 0.20, 2.28 ± 0.20, 2.12 ± 0.18 and 1.47 ± 0.14, respectively. There were no significant differences in SERT availability between men and women (p < 0.05). CONCLUSION The results of this study showed that 4-[(18)F]-ADAM was safe for human studies and its distribution in human brain appeared to correlate well with the known distribution of SERT in the human brain. In addition, it had high specific binding and a reasonable optimal time for imaging brain SERT in humans. Thus, 4-[(18)F]-ADAM may be feasible for assessing the status of brain SERT in humans.
Collapse
Affiliation(s)
- Wen-Sheng Huang
- Department of Nuclear Medicine, PET Center, Tri-Service General Hospital, 325 Sec. 2 Cheng-Kung Rd, Neihu, Taipei, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Synthesis and comparison of 4-[18F]F-ADAM, 2-[18F]F-ADAM, N-Desmethyl-4-[18F]F-ADAM and [18F]F-AFM as serotonin transporter imaging agents. Appl Radiat Isot 2012; 70:2298-307. [DOI: 10.1016/j.apradiso.2012.06.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2012] [Revised: 04/25/2012] [Accepted: 06/05/2012] [Indexed: 11/22/2022]
|
15
|
Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessl K, Hou C, Kung HF. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl Med Biol 2010; 37:479-86. [PMID: 20447560 DOI: 10.1016/j.nucmedbio.2010.01.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2009] [Revised: 01/14/2010] [Accepted: 01/27/2010] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The utility of [(18)F]FPBM [2-(2'-((dimethylamino)methyl)-4'-(3-[(18)F]-fluoropropoxy)phenylthio)benzenamine], a selective serotonin transporter (SERT) tracer, and [(18)F]AV-133 [(+)-2-Hydroxy-3-isobutyl-9-(3-fluoropropoxy)-10-methoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine], a selective vesicular monoamine transporter 2 (VMAT2) tracer, were tested in the 6-hydroxydopamine (6-OHDA) unilateral lesioned rat model. METHODS Positron emission tomography (PET) imaging of three 6-OHDA unilateral lesioned male Sprague Dawley rats (Rats 1-3) were performed with [(18)F]FPBM and [(18)F]AV-133 to examine whether changes in SERT and VMAT2 binding, respectively, could be detected in the brain. The brains of the three rats were then removed and examined by in vitro autoradiography with [(18)F]FPBM and the dopamine transporter ligand, [(125)I]IPT [N-(3'-[(125)I]-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chloro phenyl) tropane, for confirmation. Biodistribution of [(18)F]FPBM in a separate group of p-chloroamphetamine (PCA) treated rats were also performed. RESULTS PET image analysis showed varying levels of SERT binding reduction (Rat 1=-11%, Rat 2=-4%, Rat 3=-43%; n=2) and a clear and definitive loss of VMAT2 binding (Rat 1=-87%, Rat 2=-72%, and Rat 3=-91%; n=1) in the left striatum when compared to the right (non-lesioned side) striatum. The results from PET imaging were corroborated with quantitative in vitro autoradiography. Rats treated with a selective serotonin toxin (p-chloroamphetamine) showed a significant reduction of [(18)F]FPBM uptake in the cortex and hypothalamus regions of the brain. CONCLUSION The preliminary data suggest that [(18)F]FPBM and [(18)F]AV-133 may be useful for the examination of serotonergic and dopaminergic neuron integrity, respectively, in the living brain.
Collapse
Affiliation(s)
- Julie L Wang
- Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Wang JL, Deutsch EC, Oya S, Kung HF. FlipADAM: a potential new SPECT imaging agent for the serotonin transporter. Nucl Med Biol 2010; 37:577-86. [DOI: 10.1016/j.nucmedbio.2010.02.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2009] [Revised: 02/09/2010] [Accepted: 02/27/2010] [Indexed: 10/19/2022]
|
17
|
Jarkas N, Voll RJ, Williams L, Goodman MM. Validation of two fluoro-analogues of N,N-dimethyl-2-(2′-amino-4′-hydroxymethyl-phenylthio)benzylamine as serotonin transporter imaging agents using microPET. Nucl Med Biol 2010; 37:593-603. [DOI: 10.1016/j.nucmedbio.2010.03.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Revised: 02/25/2010] [Accepted: 03/08/2010] [Indexed: 11/17/2022]
|
18
|
Mavel S, Meheux N, Guilloteau D, Emond P. Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands. Bioorg Med Chem 2010; 18:236-41. [DOI: 10.1016/j.bmc.2009.10.062] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 10/28/2009] [Accepted: 10/30/2009] [Indexed: 11/24/2022]
|
19
|
Wang JL, Parhi AK, Oya S, Lieberman B, Kung HF. In Vivo Characterization of a Series of 18F-Diaryl Sulfides (18F-2-(2′-((Dimethylamino)Methyl)-4′-(Fluoroalkoxy)Phenylthio)Benzenamine) for PET Imaging of the Serotonin Transporter. J Nucl Med 2009; 50:1509-17. [DOI: 10.2967/jnumed.108.060723] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
20
|
Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Camp VM, Malveaux EJ, Votaw JR, Howell L, J.Owens M, Goodman MM. Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 2008; 51:7788-99. [PMID: 19053782 PMCID: PMC2668213 DOI: 10.1021/jm800781a] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
The meta-vinylhalide fluoroalkyl ester nortropanes 1-4 were synthesized as ligands of the serotonin transporter (SERT) for use as positron emission tomography (PET) imaging agents. In vitro competition binding assays demonstrated that 1-4 have a high affinity for the SERT (K(i) values = 0.3-0.4 nM) and are selective for the SERT over the dopamine and norepinephrine transporters (DAT and NET). MicroPET imaging in anesthetized cynomolgus monkeys with [(18)F]1-[(18)F]4 demonstrated that all four tracers behave similarly with peak uptake in the SERT-rich brain regions achieved after 45-55 min, followed by a steady washout. An awake monkey study was performed with [(18)F]1, which demonstrated that the uptake of [(18)F]1 was not influenced by anesthesia. Chase studies with the SERT ligand 15 displaced [(18)F]1-[(18)F]4, but chase studies with the DAT ligand 16 did not displace [(18)F]1-[(18)F]4 thus indicating that the tracers were binding specifically to the SERT.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Mark M. Goodman
- To whom correspondence should be addressed. Department of Radiology, Emory University, 1364 Clifton Road NE, Atlanta, GA 30322 Phone: (404) 727-9366. Fax: (404) 727-3488. E-mail:
| |
Collapse
|
21
|
2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol 2008; 35:447-58. [PMID: 18482682 DOI: 10.1016/j.nucmedbio.2008.02.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2007] [Revised: 02/06/2008] [Accepted: 02/14/2008] [Indexed: 11/21/2022]
Abstract
INTRODUCTION A new (18)F ligand, 2-(2'-((dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine ([(18)F]1), for positron emission tomography (PET) imaging of serotonin transporters (SERT) was evaluated. METHODS Binding affinity was determined through in vitro binding assays with LLC-PK1 cells overexpressing SERT, NET or DAT (LLC-SERT, LLC-NET and LLC-DAT) and with rat cortical homogenates. Localization and selectivity of [(18)F]1 binding in vivo were evaluated by biodistribution, autoradiography and A-PET imaging studies in rats. RESULTS This compound displayed excellent binding affinity for SERT in vitro with K(i)=0.33 and 0.24 nM in LLC-SERT and rat cortical homogenates, respectively. Biodistribution studies with [(18)F]1 showed good brain uptake (1.61% dose/g at 2 min postinjection), high uptake into the hypothalamus (1.22% dose/g at 30 min) and a high target-to-nontarget (hypothalamus to cerebellum) ratio of 9.66 at 180 min postinjection. Pretreatment with a SERT selective inhibitor considerably inhibited [(18)F]1 binding in biodistribution studies. Ex vivo autoradiography reveals [(18)F]1 localization to brain regions with high SERT density, and this binding was blocked by pretreatment with SERT selective inhibitors. Small animal PET (A-PET) imaging in rats provided clear images of tracer localization in the thalamus, midbrain and striatum. In A-PET chasing experiments, injecting a SERT selective inhibitor 75 min post-tracer injection causes a dramatic reduction in regional radioactivity and the target-to-nontarget ratio. CONCLUSION The results of the biological studies and the ease of radiosynthesis with moderately good radiochemical yield (RCY=10-35%) make [(18)F]1 an excellent candidate for SERT PET imaging.
Collapse
|
22
|
Middleton DS, Andrews M, Glossop P, Gymer G, Hepworth D, Jessiman A, Johnson PS, MacKenny M, Pitcher MJ, Rooker T, Stobie A, Tang K, Morgan P. Designing rapid onset selective serotonin re-uptake inhibitors. 2: Structure–activity relationships of substituted (aryl)benzylamines. Bioorg Med Chem Lett 2008; 18:4018-21. [DOI: 10.1016/j.bmcl.2008.06.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2008] [Revised: 06/02/2008] [Accepted: 06/02/2008] [Indexed: 10/22/2022]
|
23
|
Design of Monoamine Reuptake Inhibitors: SSRIs, SNRIs and NRIs. TOPICS IN MEDICINAL CHEMISTRY 2008. [DOI: 10.1007/7355_2008_028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|